Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Net Margin: 2019-2024

Historic Net Margin for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to 104.74%.

  • Silence Therapeutics' Net Margin fell 1080837.00% to 13,181.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 249.86%, marking a year-over-year increase of 20403.00%. This contributed to the annual value of 104.74% for FY2024, which is 6663.00% up from last year.
  • Latest data reveals that Silence Therapeutics reported Net Margin of 104.74% as of FY2024, which was up 38.88% from 171.37% recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Net Margin registered a high of 104.74% during FY2024, and its lowest value of 593.17% during FY2020.
  • Moreover, its 3-year median value for Net Margin was 171.37% (2023), whereas its average is 169.19%.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 743,142bps in 2020, then plummeted by 6,009bps in 2023.
  • MRY analysis of 5 years shows Silence Therapeutics' Net Margin stood at 593.17% in 2020, then skyrocketed by 46bps to 317.36% in 2021, then rose by 27bps to 231.46% in 2022, then grew by 26bps to 171.37% in 2023, then soared by 39bps to 104.74% in 2024.
  • Its Net Margin was 104.74% in FY2024, compared to 171.37% in FY2023 and 231.46% in FY2022.